Richard N. Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, Elke Hunsche, Pavel Jansa, Franck-Olivier Le Brun, Sanjay Mehta, Tomás Pulido, Lewis J. Rubin, B.K.S. Sastry, Gérald Simonneau, Olivier Sitbon, Rogério Souza, Adam Torbicki and Nazzareno Galiè
Patient Subgroup Analyses on the Time to First All-Cause Hospitalization
Patient subgroup analyses of the effects of 3 mg of macitentan (A) and 10 mg of macitentan (B) on the time to first hospitalization due to any cause. *”Other” causes consist of idiopathic or heritable pulmonary arterial hypertension (PAH) or PAH related to human immunodeficiency virus infection or drugs and toxins.